Vorasidenib approved in UK for treating IDH-mutant brain tumours
MHRA greenlights oral therapy for patients aged 12 and over with grade 2 astrocytoma The MHRA has approved vorasidenib (Voranigo)...
Medicine
Imfinzi approved for NHS use in limited-stage small cell lung cancer
Durvalumab becomes first immunotherapy recommended for LS-SCLC patients in England and Wales AstraZeneca’s Imfinzi (durvalumab) has been approved for NHS...
SOM Biotech receives EMA backing for Huntington’s disease drug
Positive orphan drug opinion supports SOM3355’s potential as first-line treatment in Europe SOM Biotech has received a positive opinion from...
Dr Christian Dowdeswell – PharmaTimes
Arcinova has appointed Dr Christian Dowdeswell as Managing Director Arcinova, a Quotient Sciences company and UK-based contract research development and manufacturing organisation...
Lundbeck unveils migraine data for eptinezumab at international congress
New phase 4 results show sustained symptom relief and improved patient outcomes Lundbeck has presented new clinical data on eptinezumab...
Capvaxive shows strong immune response in children at risk of pneumococcal disease
Merck presents phase 3 STRIDE-13 trial results at ESCMID conference in Lisbon Merck has announced positive phase 3 results for...
George Eldridge – PharmaTimes
Abcuro has appointed George Eldridge as chief financial officer Abcuro Inc, a clinical-stage biotechnology company developing therapies for the treatment of...
Rezatapopt shows promise in phase 2 trial for TP53 Y220C solid tumours
Early data reveals strong response rates in ovarian cancer cohort PMV Pharma has announced encouraging interim results from the phase...
Bluejay begins phase 3 trial of brelovitug for hepatitis D
First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex Bluejay Therapeutics has enrolled the first patient in AZURE-2, a...
Quotient Sciences and CPI launch RNA drug development venture
New partnership aims to fast-track mRNA therapies from lab to clinic Quotient Sciences and CPI have signed a memorandum of...
Eisai unveils promising phase 1b data for narcolepsy drug E2086
Novel orexin receptor agonist shows potential to improve wakefulness Eisai has presented new clinical data for its investigational orexin 2...
Sharon Curran – PharmaTimes
Sharon Curran has been appointed Chair of Rosemont's board Sharon Curran has been appointed as the new chairperson for Rosemont Pharmaceuticals board of directors. The...
AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025
Topical TRPV1 antagonist shows promise in heat-induced neuropathic pain lzeCure Pharma has presented new clinical data on its lead pain...
Centre stage
Survey reveals lack of awareness need for greater clarity
Resolution Therapeutics doses first patient in EMERALD study of RTX001
Trial explores regenerative macrophage therapy for liver disease Resolution Therapeutics has announced that the first patient has been dosed and...
Promised land
Blended solutions gain momentum and reveal untapped potential
eXmoor and Anthony Nolan partner to streamline cell therapy development
Collaboration offers end-to-end support from donor sourcing to manufacturing eXmoor Pharma and Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS)...
Polpharma Biologics and MS Pharma partner to expand biosimilar access
Deal covers biosimilars for gastroenterology, neurology and dermatology Polpharma Biologics has signed licensing agreements with MS Pharma for the commercialisation...
Lilly receives UK approval for pirtobrutinib in relapsed blood cancers
MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma Eli Lilly and Company has received conditional marketing authorisation from...
FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease
New subcutaneous autoinjector offers at-home treatment option for patients Eisai and Biogen have announced FDA approval of LEQEMBI IQLIK (lecanemab-irmb)...
Coya Therapeutics to progress trial of ALS treatment upon FDA approval
The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application from Coya Therapeutics for COYA...
Akiram advances trial of targeted radiotherapy for solid tumours
Swedish biotech company Akiram Therapeutics has announced significant progress in its first clinical trial of AKIR001, a radiopharmaceutical intended to...
Johnny Cheng appointed as interim CEO of HUTCHMED
HUTCHMED has announced that Weiguo Su, CEO of the company, will take a leave of absence from his duties due...
Encare’s ERAS system gains Mayo Clinic qualification, strengthening global reach
Encare’s ERAS Interactive Audit System (EIAS) has earned qualification on the Mayo Clinic Platform_Solutions Studio – a distinction rarely awarded...
Anne White to retire as head of Lilly Neuroscience after three decades at company
Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience, will retire at...
Novartis blood disorder drug shows promise in late-stage trial
Novartis has reported that its experimental drug ianalumab met the primary goal in a phase 3 trial for primary immune...
Fertile ground – PharmaTimes
Top-rated pharmacies in northern Virginia for personalised fertility care Finding the right pharmacy to support your fertility journey is essential....
Friends of Cancer Research and MMS partner to improve interpretation of cancer trial survival data
Friends of Cancer Research has announced a new collaboration with global clinical research organisation, MMS, to develop decision frameworks that...
ANGLE partners with Myriad Genetics to explore blood-based cancer testing
ANGLE has announced a collaboration with Myriad Genetics to assess whether circulating tumour cell (CTC) DNA harvested from blood samples...
FDA grants Breakthrough Therapy Designation to lung cancer therapy
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren), an investigational drug...
Upperton Pharma Solutions awarded grant to develop oral vaccine delivery with University of Oxford
Upperton Pharma Solutions has been awarded funding under the first VaxHub Sustainable Platform Funding Call to support the development of...
Upperton and Oxford join forces to develop oral vaccine formulation
Project aims to improve global immunisation through needle-free delivery Upperton Pharma Solutions has secured funding from the first VaxHub Sustainable...
Ogsiveo approved in EU for treatment of desmoid tumors
Merck’s therapy becomes first authorised option for aggressive soft tissue tumours Merck has announced that the European Commission has granted...
Scotland approves zanubrutinib for relapsed mantle cell lymphoma
New treatment option now available across all UK nations Patients in Scotland with relapsed or refractory mantle cell lymphoma (MCL)...
Sever Pharma expands work on ketamine implant with Silo Pharma
New phase of development targets chronic pain and fibromyalgia Sever Pharma Solutions has deepened its partnership with Silo Pharma to...
Mounjaro shows cardiovascular benefit in head-to-head diabetes trial
Lilly’s study finds tirzepatide delivers broader health improvements Eli Lilly has announced positive topline results from its phase 3 SURPASS-CVOT...
Vedanta’s ulcerative colitis candidate misses phase 2 efficacy target
Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection Vedanta Biosciences has announced that VE202 failed...
Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial
Promising results support global submissions and priority review by US FDA Genmab has announced that its phase 3 EPCORE FL-1...
FDA approves AJOVY for paediatric migraine prevention
Teva’s CGRP therapy becomes first approved option for children and adolescent Teva Pharmaceuticals has received US FDA approval for AJOVY...
Lilly and UK Government launch £85 million obesity care innovation programme
Nationwide competition to pilot new models of obesity support Eli Lilly and Company and the UK Government have announced a...
Lilly’s Jaypirca shows positive results in phase 3 trial
Pirtobrutinib meets primary endpoint in CLL/SLL study Eli Lilly and Company has announced positive topline results from its phase 3...
FDA expands AVTOZMA IV approval to include cytokine release syndrome
Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US Celltrion has received US Food and Drug Administration approval...
NICE backs KEYTRUDA combination for advanced endometrial cancer
New first-line option for patients with pMMR and dMMR tumours in England NICE has recommended KEYTRUDA (pembrolizumab) with carboplatin and...
Porosome Therapeutics unveils breakthrough Alzheimer’s research
FDA validation and AI-designed therapies mark major shift in treatment strategy Porosome Therapeutics has announced major advances in Alzheimer’s disease...
Nxera unveils proprietary pipeline targeting obesity and metabolic disorders
New oral GLP-1 agonist aims to reshape chronic weight management Nxera Pharma has launched a broad proprietary pipeline focused on...
Gedeon Richter launches Nalvee in UK to expand HRT options for menopause
Dydrogesterone-only tablet returns after 17-year absence to support personalised care Gedeon Richter UK has launched Nalvee (10mg dydrogesterone) in the...
Bath researchers develop pill-based alternative to injections
New drug delivery system could transform treatment for chronic conditions Scientists at the University of Bath have developed a new...
Microbiotica completes recruitment for phase 1b ulcerative colitis trial
MB310 study investigates safety and efficacy of precision microbiome therapy Microbiotica has completed patient recruitment for its phase 1b trial,...
US$30.9 million strategic equity deal strengthens Everest’s oncology platform
US$30.9 million strategic equity deal strengthens oncology platform Everest Medicines has announced a strategic equity investment of US$30.9 million in...
Moderna wins EU approval for updated COVID-19 vaccine
Spikevax authorised to target LP.8.1 variant ahead of 2025-2026 season Moderna has received marketing authorisation from the European Commission for...
Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease
Four-year treatment slows cognitive decline with consistent safety profile Eisai has presented new clinical data showing that patients with early...
NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer
Imfinzi and Imjudo combination recommended as first-line treatment AstraZeneca has received a positive recommendation from NICE for the use of...
Filgotinib meets phase 3 endpoint in axial spondyloarthritis trial
Alfasigma to seek regulatory approval following OLINGUITO study success Alfasigma has announced positive topline results from its OLINGUITO phase 3...
PharmaTimes Clinical Researcher of the Year – The Americas
Still time to enter – but not much! Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!...
Exonate to launch phase 2b trial of EXN407 for diabetic eye disease
CLEAR-DE study to assess topical therapy for non-proliferative diabetic retinopathy Exonate has announced plans to initiate a phase 2b clinical...
Elizabeth Rebeil – PharmaTimes
Veranova has appointed Elizabeth Rebeil as VP of Supply Chain Excellence Veranova has appointed Elizabeth Rebeil as Global Vice President of Supply Chain and Operational Excellence....
Moderna’s updated COVID-19 vaccine receives positive EMA opinion
CHMP recommends authorization for LP.8.1-targeting vaccine ahead of 2025-2026 season Moderna has received a positive opinion from the European Medicines...
Kling Bio partners with Sanofi to accelerate antibody discovery
Collaboration aims to advance next-generation therapeutics and vaccines Kling Bio has announced a new collaboration and licence option agreement with...
Akari Therapeutics advances research on novel PH1 payload for targeted cancer therapy
Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in its antibody...
Ovagen breakthrough boosts yellow fever vaccine yields
Irish biotech’s germ-free egg platform could help close global shortfall Irish biotech Ovagen has announced a major advance in vaccine...
4TEEN4 begins trial of antibody therapy for cardiogenic shock
First patient dosed in phase 1b/2a study of procizumab 4TEEN4 Pharmaceuticals has dosed the first patient in a phase 1b/2a...
PharmaTimes Clinical Researcher of the Year – The Americas
Enter this year's thrilling competition! Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Clinical...
PhoreMost unveils platform to streamline molecular glue drug discovery
GlueSEEKER enables rational design of targeted protein degraders PhoreMost has published new data validating its GlueSEEKER platform, a high-throughput technology...
Ezmekly becomes first approved EU therapy for NF1-PN in children and adults
EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics The European Commission has approved EZMEKLY (mirdametinib) for treatment of...
AlzeCure to present promising pain therapy ACD440 at NeuPSIG 2025
Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients AlzeCure Pharma will present new clinical data...
One Biosciences raises €15 million to advance single-cell oncology platform
Funding to accelerate development of AI-driven tumour profiling tool OneMap One Biosciences has secured €15 million in Series A financing...
Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression
First patient dosed in BUOY-1 study targeting MDD with or without anxious distress Seaport Therapeutics has dosed the first patient...
Proximie and HistoSonics partner to transform liver tumour treatment in US
Digital operating rooms and histotripsy therapy combine to improve outcomes Proximie has announced a new partnership with HistoSonics to support...
North East NHS launches digital platform to tackle chronic kidney disease
Healthinote rollout aims to improve early detection and patient self-management North East and North Cumbria NHS has begun a year-long...
MHRA approves first oral treatment for hereditary angioedema attacks
Sebetralstat offers injection-free relief for patients aged 12 and over The MHRA has approved sebetralstat (Ekterly) as the first oral,...
NHS England secures access to new cystic fibrosis treatment ALYFTREK
Vertex’s once-daily triple therapy approved for eligible patients aged six and over Vertex Pharmaceuticals has announced a broad reimbursement agreement...
Imperial study reveals DNA structure that could reverse ovarian cancer resistance
Researchers at Imperial College London have discovered that an unusual DNA structure could be key to reversing chemotherapy resistance in...
Pierre Fabre secures China approval for BRAFTOVI combination in colorectal cancer
New treatment targets BRAFV600E-mutant mCRC after prior therapy Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib)...
Osivax publishes phase 2a results supporting dual flu vaccine approach
OVX836 shown to be safe and effective alongside seasonal Fluarix Tetra Osivax has released phase 2a trial data confirming that...
Government to adopt EU standards for high-risk diagnostic devices
New regulations aim to simplify processes and strengthen patient safety The Government is set to amend UK medical devices regulations...
Actithera closes $75.5m Series A to advance radioligand therapy platform
Funding to support lead candidate targeting FAP and pipeline expansion Actithera has secured $75.5 million in an oversubscribed Series A...
BiomX phage therapy shows potent effect in cystic fibrosis trial
BX004 achieves 500-fold bacterial reduction with no resistance in phase 1b/2a study BiomX has published promising phase 1b/2a trial results...
Clinical Researcher of the Year – The Americas
Enter the 2025 PharmaTimes Clinical Researcher of the Year – The Americas Enter The 2025 PharmaTimes Clinical Researcher of the...
VarmX secures US approval to begin phase 3 trial of urgent surgery treatment
New trial to test VMX-C001’s effectiveness in restoring coagulation in FXa DOAC patients Biotech company VarmX has received clearance from...
Eladynos recommended for osteoporosis treatment in Scottish NHS
SMC approval provides option for postmenopausal women at risk of fractures The Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for...
First patient dosed in trial for novel dry AMD treatment PST-611
PulseSight begins phase 1 safety study of gene therapy for geographic atrophy PulseSight Therapeutics has announced that the first patient...
First German haemophilia B patient receives gene therapy HEMGENIX
CSL Behring marks new era in treatment with milestone reimbursement model The first haemophilia B patient in Germany has been...
Paul Carter – PharmaTimes
Clinigen has appointed Paul Carter as Non-Executive Chair of its Board Clinigen, the global pharmaceutical services Group, has appointed seasoned biopharma...
Neumifil shows promise in treating influenza with positive phase 2 dat
Pneumagen’s intranasal antiviral demonstrates reduced infection Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil,...
Dr Dietrich Stephan – PharmaTimes
Enhanced Genomics appoints Dr Dietrich Stephan as Chair of the Board Enhanced Genomics has appointed Dr Dietrich Stephan as Chair of the Board of...
Moderna flu vaccine shows superior results in phase 3 study
Data shows mRNA-1010 could better protect adults aged 50 and above Moderna has reported positive phase 3 results for its...
Kate Woolland – PharmaTimes
Closed Loop Medicine has appointed Kate Woolland as CEO Closed Loop Medicine (CLM) has appointed Kate Woolland as Chief Executive Officer. Previously serving...
Cidara and hVIVO report positive results in flu prevention study
New data show strong efficacy of CD388 in phase 2b trial Cidara Therapeutics and hVIVO have announced encouraging topline results...
UCB reports success in phase 3 study of fenfluramine for CDD
Positive trial results offer hope for those with ultra-rare epileptic disorder UCB has announced that its phase 3 trial evaluating...
Future prescribed – PharmaTimes
Transforming community prescribing through innovation As the NHS places an increasing focus on strengthening primary care and enhancing community-based prescribing,...
Talking the talk
Why supporting representative trial participation matters
NHS ConfedExpo 2025: a platform for change in UK health and care
This year's event took place on 11 to 12 June at Manchester Central This year’s NHS ConfedExpo took place on...
Jessica Atkinson – PharmaTimes
VectorY Therapeutics has appointed Jessica Atkinson as Chief Business Officer VectorY Therapeutics has appointed Jessica Atkinson as Chief Business Officer. In this newly created role, she...
2025 PharmaTimes Clinical Researcher of the Year
Enter this year's famous competition Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Novice...
Excellence in Healthcare Partnerships Awards launched by PMGroup and Visions4Health
The programme was unveiled at this year’s NHS ConfedExpo in Manchester PMGroup Worldwide and Visions4Health have launched the Excellence in...
Ben Svarczkopf – PharmaTimes
Biocartis has appointed Ben Svarczkopf as Senior Vice President of Global Marketing Biocartis Group of Companies (Biocartis) has announced the...
NHS rolls out new initiative to identify pancreatic cancer earlier
The pilot will see GP practices look at patient records to identify those most at risk The NHS has announced...
Chris Brett – PharmaTimes
Kallikor has appointed Chris Brett as Chief Technology and Product Officer Kallikor has announced the appointment of Chris Brett as...
eXmoor and Signadori Bio enter cell therapy partnership
Signadori is advancing a platform designed to overcome the challenges of treating solid cancers eXmoor Pharma and Signadori Bio have...
Louise Peacock – PharmaTimes
Aravax has appointed Louise Peacock as Chief Regulatory and Quality Officer Aravax has announced the appointment of Louise Peacock as...
Teva and Fosun Pharma partner on early-stage oncology drug
The candidate is being evaluated as both a monotherapy and in combination pembrolizumab Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical...
Steven Sciuto – PharmaTimes
iOnctura has appointed Steven Sciuto as Chief Financial Officer iOnctura has announced the appointment Steven Sciuto as its new Chief...
FDA approves UroGen’s Zusduri to treat recurrent bladder cancer
Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US The US Food and Drug Administration (FDA) has...
Investigational treatment shows promise for aggressive multiple myeloma
Results suggest bispecific antibody combination could improve outcomes A new investigational treatment has shown strong and lasting responses in multiple...
EDX medical partners with spire healthcare to advance disease diagnostics
Collaboration aims to improve rapid detection and personalised treatments EDX Medical Group has entered into an agreement with Spire Healthcare...
Dr Jason Slingsby – PharmaTimes
Tozaro has appointed Dr Jason Slingsby as Chief Executive Officer Tozaro has announced the appointment of Dr Jason Slingsby as Chief Executive Officer. Jason will lead...
Argenx presents new efgartigimod data at EULAR 2025
Rheumatology studies show promising results for Sjogren’s disease Argenx has presented positive phase 2 results for efgartigimod in myositis and...
Migraine takes the spotlight at European Parliament
EMHA calls for its inclusion in EU neurological health strategy The European Migraine and Headache Alliance (EMHA) has urged EU...
Levicept presents new LEVI-04 data at EULAR
Biotech firm shares phase 2 findings on novel osteoarthritis treatmen Levicept has presented new data from its phase 2 trial...
Bimekizumab shows lasting efficacy at EULAR 2025
Three-year data highlights inflammation control in psoriatic arthritis UCB has announced new three-year data from phase 3 trials and their...
Unique journey
Personalisation is the future of cancer care
Nihad Hasagic – PharmaTimes
Clinigen has appointed Nihad Hasagic as SVP for CLS Clinigen has appointed Nihad Hasagic as Senior Vice President for Clinigen Lifecycle Services (SVP CLS). CLS plays...
Tagomics secures £860k grant for colorectal cancer test
Biotech firm to collaborate with NHS on early detection study Tagomics has been awarded £860k in funding from Innovate UK’s...
PharmaTimes Clinical Researcher of the Year – The Americas
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Enter The 2025 PharmaTimes Clinical Researcher of the...
Dr Jason Slingsby – PharmaTimes
Tozaro has announced the appointment of Dr Jason Slingsby as Chief Executive Officer. Jason will lead the company’s long-term strategy, including commercialisation of...
Linear Diagnostics awarded £1m to develop rapid STI test
New funding supports development of diagnostic platform Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test...
EC approves Santen’s Ryjunea to slow progression of paediatric myopia
Therapy indicated for children aged 3 to 14 at treatment initiation Santen has announced that the European Commission has granted...
NICE recommends Sogroya for growth hormone deficiency in children
Treatment provides option for children with growth failure The National Institute for Health and Care Excellence (NICE) has recommended Sogroya...
Patient puzzle – PharmaTimes
Last month, I had the privilege of hosting a webinar for the National Institute for Health and Care Research (NIHR)...
Leading lights
Richard Condon, CEO Aspire Pharma, discusses successful leadership
PharmaTimes Clinical Researcher of the Year – The Americas
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Enter The 2025 PharmaTimes Clinical Researcher of the...
AstraZeneca’s Forxiga recommended for chronic kidney disease treatment
Updated guidance from NICE expands eligibility for dapagliflozin us The National Institute for Health and Care Excellence (NICE) has published...
NICE recommends mirikizumab for Crohn’s disease treatment
New guidance expands treatment options for eligible patients The National Institute for Health and Care Excellence (NICE) has issued final...
Stephen Rayda – PharmaTimes
Worldwide Clinical Trials has appointed Stephen Rayda as Chief Digital and Information Officer Worldwide Clinical Trials has appointed Stephen Rayda...
Lumanity and Parker Institute partner to support delivery of new immunotherapies
The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise Lumanity and the Parker Institute for...
Eli Lilly acquires SiteOne Therapeutics to advance treatment for chronic pain
Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain...
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno...
Oxford Brain Diagnostics to launch groundbreaking dementia diagnosis technology
Company secures regulatory approvals for commercial rollout in UK and US With over 55 million people worldwide living with dementia,...
NICE recommends sparsentan for IgA nephropathy
First non-immunosuppressive dual-action therapy approved for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI...
Massalia Therapeutics launches to advance novel treatments for complex conditions
Biotech spin-off targets fibrosis, neoplasm and neovascularization Massalia Therapeutics, a biotechnology spin-off from the C2VN Institute, has officially launched with...
Sonrai and AOA Dx partner to accelerate ovarian cancer test development
Strategic collaboration aims to improve early diagnosis Sonrai Analytics and AOA Dx have announced a partnership to accelerate the development...
MHRA Board meets in Scotland for first time, reinforcing UK-wide health priorities
The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time, marking...
Bee Koen Low – PharmaTimes
Kelso Pharma has appointed Bee Koen Low as Chief Operating Officer Kelso Pharma has announced the appointment of Bee Koen...
Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia
The drug was recently approved in the US for familial chylomicronaemia syndrome Ionis Pharmaceuticals has shared positive top-line results from...
Elizabeth Rebeil – PharmaTimes
Veranova has appointed Elizabeth Rebeil as Global Vice President of Supply Chain and Operational Excellence Veranova has announced the appointment...
FDA approves Amneal’s self-administered migraine drug Brekiya
Brekiya is now the first DHE auto-injector to be approved by the regulator The US Food and Drug Administration (FDA)...
MHRA approves guselkumab for Crohn’s disease and ulcerative colitis
Regulator confirms safety and efficacy of new treatment option for patient The Medicines and Healthcare products Regulatory Agency (MHRA) has...
AviadoBio opens UK trial for FTD gene therapy
Aspire-FTD study aims to stop disease progression with one-time treatment AviadoBio has launched its phase 1/2 Aspire-FTD trial in the...
Shane Olwill – PharmaTimes
Asgard Therapeutics has appointed Shane Olwill as Chief Development Officer Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell...
Kaerus Bioscience secures orphan drug designation for fragile x syndrome treatment
FDA recognises KER-0193 as a potential therapy for rare paediatric disease Kaerus Bioscience has received orphan drug and rare paediatric...
Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease
Trial progresses towards topline data expected later in the year Herantis Pharma has dosed the first patients in the final...
Rein Therapeutics initiates renew phase 2 trial for IPF treatment
Screening begins for study evaluating LTI-03 in idiopathic pulmonary fibrosi Rein Therapeutics has begun screening and recruiting patients for its...
Gergely Sved – PharmaTimes
Ellab has appointed Gergely Sved as its new Chief Executive Officer Ellab, the provider of validation, monitoring and calibration services and solutions,...
Apiary invests in life sciences marketing specialist performance-io
Private equity firm Apiary Capital backs rapid growth of performance-i Apiary Capital has completed its investment in performance-io (PIO), a...
Fiona Smith-Laittan – PharmaTimes
Fiona Smith-Laittan has been appointed Chair of Cambridge Global Health Partnerships Fiona Smith-Laittan, Vice President of Global Health Strategy and...
PharmaTimes Clinical Researcher of the Year – The Americas Awards
Demonstrate your skill and prowess by entering this year's awards! For 2025, The 2025 PharmaTimes Clinical Researcher of the Year...
iOnctura starts randomised phase 1/2 trial in lung cancer treatment
Study explores whether PI3Kδ targeting could combat resistance iOnctura has begun a randomized phase 1/2 study investigating its lead asset,...
Amgen’s Tepezza granted marketing authorisation in the UK
Teprotumumab approved as first targeted treatment for thyroid eye disease The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has...
MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d
UCB’s developmental treatment may be eligible for patient access UCB has announced that its developmental treatment DoxTM, a combination of...
Johnson & Johnson submits application for subcutaneous Rybrevant dosing
Company seeks approval for new schedules to improve patient convenience Janssen-Cilag International NV, a Johnson & Johnson company, has submitted...
Chiesi partners with Wirral Primary Care to improve COPD detection
New initiative aims to accelerate diagnosis and ease NHS pressures Chiesi UK and Ireland and Wirral Primary Care Collaborative (WPCC)...
Mosaic therapeutics expands pipeline with Astex deal
Cambridge firm in-licenses two oncology programmes Mosaic Therapeutics a UK-based oncology company has announced it has in-licensed two clinical-stage oncology...
Nice recommends first AI medical device for skin cancer diagnosis in the NHS
Approval marks milestone for AI use in frontline care NICE has endorsed DERM, an autonomous AI medical device developed by...
Leqembi dosing proposal for Alzheimer’s treatment validated by MHRA
Application seeks reduced infusion frequency to support patient flexibility Eisai Europe and Biogen Idec have announced the validation of a...
Hundreds of genetic links to osteoarthritis unlocked
Study paves the way for personalised therapies for osteoarthritis sufferer Groundbreaking research has identified over 900 genetic links to osteoarthritis,...
Lynozyfic receives EU approval for relapsed multiple myeloma treatment
New therapy offers hope for patients with limited option Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved...
Katharina Pink – PharmaTimes
Aspire Pharma has appointed Katharina Pink as Chief Commercial Officer Aspire Pharma has announced the appointment of Katharina Pink as...
Shaping tomorrow
Today’s leaders are building a stronger, more inclusive future for the industry
Takeda’s Adcetris receives positive opinion for Hodgkin lymphoma treatment
CHMP recommendation brings new hope for patients Takeda has announced a positive opinion from the Committee for Medicinal Products for...
Argenx receives positive CHMP opinion for CIDP treatment
VYVGART could be the first CIDP drug with a novel mechanism in 30 years Argenx has announced that the Committee...
Noah Goodman – PharmaTimes
Kymera Therapeutics has appointed Noah Goodman as Chief Business Officer Clinical-stage biopharma Kymera Therapeutics has announced the appointment Noah Goodman...
UCL researchers launch congenital muscular dystrophy research programme
The university has been awarded a £1m grant from LifeArc and Muscular Dystrophy UK Researchers from University College London (UCL)...
Acoramidis approved for heart condition treatment
MHRA authorises drug for adults with rare heart muscle damage The Medicines and Healthcare products Regulatory Agency (MHRA) has given...
Mosaic therapeutics expands pipeline with Astex deal
Mosaic Therapeutics a UK-based oncology company has announced it has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals. The agreement...
All systems go! – PharmaTimes
Where to purchase reliable pharmacy automation systems Technological advancements propel the pharmaceutical industry into the future. Better equipment makes it...
Patrick Daly – PharmaTimes
Terumo BCT has appointed Patrick Daly as Chief Business Officer Terumo Blood and Cell Technologies (Terumo BCT) has announced the...
Genomics study launches to optimise childhood cancer care in Ireland
It is hoped that the MAGIC-I study will support earlier diagnosis and personalised treatment A five-year clinical study aiming to...
Russell Abberley – PharmaTimes
ABPI has appointed Russell Abberley as President-elect The Association of the British Pharmaceutical Industry (ABPI) has appointed Russell Abberley, Vice...
Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine Novavax has shared positive preliminary results from a...
Aidan Synnott – PharmaTimes
Oncodesign Services has appointed Aidan Synnott as CEO Oncodesign Services has announced the appointment of Aidan Synnott as its new...
FDA approves Click’s digital therapeutic for episodic migraine
More than 37 million adults in the US are affected by migraine The US Food and Drug Administration (FDA) has...
New test prototype for monitoring MGUS patients funded
Birmingham researchers to make MGUS monitoring more efficient Birmingham researchers have received £230k from Cancer Research Horizons to develop a...
Leqembi approved as first treatment to slow early Alzheimer’s progression
European Commission grants authorisation for Eisai and Biogen therapy The European Commission has granted marketing authorisation for Leqembi (lecanemab), making...
Pepaxti shows effectiveness in heavily pretreated multiple myeloma patients
New real-world data reinforce treatment benefit Real-world data from the University of Catania, Italy, suggest that Pepaxti, a treatment for...
Global data highlights effectiveness of romosozumab
Studies show improved bone mineral density and healthcare cost reductions New data from multiple countries confirm the effectiveness of romosozumab,...
New data reinforce daratumumab as standard of care for multiple myeloma
Long-term survival projections suggest improved outcomes for patients New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet...
UK clinical trials regulations signed into law
Major update aims to accelerate research and strengthen patient safety New UK clinical trials regulations have been signed into law,...
Lab-grown lung cancer cells show potential to revolutionise treatment
The model could lead to more targeted treatments for the disease Cancer Research scientists have developed a new cell-based model...
First treatment for common bladder cancer recommended by NICE
Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration Balversa (erdafitinib)...
SkyCell and Microsoft partner to improve pharma supply chains
AI-powered SkyMind is designed to improve efficiency, compliance and decision-making SkyCell has partnered with Microsoft to launch SkyMind, an artificial...
NHS launches spring COVID-19 booster campaign
An estimated 7.5 million people will be invited to receive the booster The NHS has started delivering its spring COVID-19...
Regina Hodits – PharmaTimes
Angelini Ventures has appointed Regina Hodits as managing director Angelini Ventures has announced the appointment of Regina Hodits as its...
MHRA approves prostate cancer imaging agent trofolastat
Approximately 55,100 new cases of prostate cancer are diagnosed every year in the UK The Medicines and Healthcare products Regulatory...
SMC approves bimekizumab for hidradenitis suppurativa treatment
The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have...
Endlyz Therapeutics emerges with pipeline for Parkinson’s disease
Research targets lysosomal function restoration for neurodegeneration Endlyz Therapeutics has launched from stealth, unveiling its pipeline of small molecule modulators...
Aspire and inspire – PharmaTimes
Women are shaping new dimensions throughout industry Having women in the pharmaceutical industry is crucial because it brings diverse perspectives...
Visionaries
Women in healthcare and pharma – progress, challenges and outcomes
Elekta and Azra AI partner to advance cancer registry operations with AI
Collaboration introduces automation to enhance efficiency Elekta has announced a partnership with Azra AI to improve cancer registry workflows using...
European Commission approves ustekinumab for paediatric Crohn’s disease
Approval extends ustekinumab’s use to younger patients The European Commission (EC) has approved ustekinumab for the treatment of moderately to...
NICE recommends brentuximab vedotin plus AVD for Hodgkin lymphoma
Advancing care for stage 3 or 4 Hodgkin lymphoma patients The National Institute for Health and Care Excellence (NICE) has...
4basebio receives MHRA licence for synthetic DNA manufacture
GMP certification enables 4basebio to supply DNA for clinical trials 4basebio PLC has been granted Good Manufacturing Practice (GMP) certification...
Diagnexia and Stratipath link up brings AI breast cancer diagnostics to UK
Collaboration expands AI-based risk profiling tools Diagnexia has announced a partnership with Stratipath AB to bring Stratipath Breast, an AI-based...
Bio matters
Are biotechs underestimating regulatory groundwork
One Health – PharmaTimes
The vital link between human and animal well-being The next pandemic will require crucial collaboration between veterinarians and medical professionals....
Gene team – PharmaTimes
When Integrated DNA Technologies (IDT) launched its Collab Network in February 2023, the goal was to speed up the pace...
Amivantamab plus lazertinib shows survival benefit in lung cancer
Janssen drug combination extends life expectancy during trial Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study,...
Genome editing offers hope for genetic hearing loss
New therapy developed to repair GJB2 R75W mutation Scientists from Juntendo University and The University of Tokyo have created an...
Nouscom reveals promising results for lynch syndrome immunotherapy
NOUS-209 shows potential to intercept cancer in its early stages Nouscom has announced full safety and immunogenicity results from its...
Linda Härmark – PharmaTimes
Drug Safety Research Unit appoints Linda Härmark as its Director The Drug Safety Research Unit has announced Linda Härmark as its new Director. She succeeds...
Kieron Hall – PharmaTimes
Sygnature Discovery has appointed Kieron Hall as Chief Commercial Officer Sygnature Discovery has announced the appointment of Kieron Hall as its new Chief Commercial Officer (CCO)...
